Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

OBJECTIVES: To perform a literature review and develop recommendations for the use of rituximab in ANCA-associated vasculitis. METHODS: A committee of experts (five rheumatologists, five nephrologists and one paediatrician) conducted a modified Delphi exercise to identify five topics for a systemat...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Guerry, M, Brogan, P, Bruce, I, D'Cruz, D, Harper, L, Luqmani, R, Pusey, C, Salama, A, Scott, D, Savage, C, Watts, R, Jayne, DR
Format:	Journal article
Język:	English
Wydane:	2012

Podobne zapisy

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
od: Flossmann, O, i wsp.
Wydane: (2006)

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.
od: Latimer, N, i wsp.
Wydane: (2014)

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
od: Latimer, N, i wsp.
Wydane: (2014)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
od: Hellmich, B, i wsp.
Wydane: (2007)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
od: Basu, N, i wsp.
Wydane: (2014)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
od: Mukhtyar, C, i wsp.
Wydane: (2006)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
od: Luqmani, R, i wsp.
Wydane: (2017)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
od: Pearce, F, i wsp.
Wydane: (2017)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
od: Mukhtyar, C, i wsp.
Wydane: (2008)

The United Kingdom and Ireland Vasculitis Registry: Cross-sectional data on the first 3195 patients with a focus on anti-neutrophil cytoplasm – associated vasculitis and giant cell arteritis
od: Luqmani, R, i wsp.
Wydane: (2017)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
od: Robson, J, i wsp.
Wydane: (2017)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
od: Merkel, P, i wsp.
Wydane: (2009)

Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
od: Feldmann, M, i wsp.
Wydane: (2006)

Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis
od: Enrique Morales, i wsp.
Wydane: (2025-01-01)

Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?
od: Saket Jha, i wsp.
Wydane: (2019-01-01)

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
od: de Groot, K, i wsp.
Wydane: (2009)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
od: Robson, J, i wsp.
Wydane: (2014)

Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians
od: David Massicotte-Azarniouch, i wsp.
Wydane: (2024-08-01)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
od: Jones, R, i wsp.
Wydane: (2010)

The role of neutrophils in vasculitis associated with antineutrophil cytoplasmic antibodies
od: E. N. Vorkel, i wsp.
Wydane: (2024-12-01)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
od: Robson, J, i wsp.
Wydane: (2017)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
od: Jones, R, i wsp.
Wydane: (2009)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
od: Luqmani, R, i wsp.
Wydane: (2017)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation
od: Valentina Binda, i wsp.
Wydane: (2021-12-01)

Late Onset of Rivaroxaban-Associated Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
od: Muskan Agarwal MD, i wsp.
Wydane: (2023-10-01)

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.
od: Walsh, M, i wsp.
Wydane: (2011)

Cardiovascular and Cerebrovascular Outcomes in Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis
od: Shiyu Xiao, i wsp.
Wydane: (2024-01-01)

Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
od: Christopher Maximilian Arends, i wsp.
Wydane: (2020-06-01)

Eular recommendations for vasculitis
od: Luqmani, R, i wsp.
Wydane: (2007)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
od: Lapraik, C, i wsp.
Wydane: (2007)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
od: Ntatsaki, E, i wsp.
Wydane: (2014)

Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
od: Weijun Liu, i wsp.
Wydane: (2024-05-01)

Recent advances in the diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
od: Si-wei Tang, i wsp.
Wydane: (2024-03-01)

Oral Microbiota Profile in Patients with Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
od: Anders Esberg, i wsp.
Wydane: (2022-08-01)

Cardiovascular involvement in primary systemic vasculitis.
od: Mukhtyar, C, i wsp.
Wydane: (2009)

Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
od: Robson, J, i wsp.
Wydane: (2016)

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis
od: CM Wortel, i wsp.
Wydane: (2025-02-01)

Health-related quality of life after Rituximab treatment of patients with antineutrophil cytoplasmic antibody-associated vasculitis
od: Iva Parvova, i wsp.
Wydane: (2024-11-01)

A Case of Postcoronavirus Disease 2019 Antineutrophil Cytoplasmic Antibody-associated Vasculitis Successfully Treated with Rituximab
od: Mahmoud M. Mohamed, i wsp.
Wydane: (2023-07-01)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
od: McLaren, J, i wsp.
Wydane: (2001)